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Inflammation is an important contributor to the aetiology of a number of bladder dysfunctions including interstitial cystitis, painful
bladder syndrome, and overactive bladder.The aim of this study was to examine the effects of inflammatorymediators on urothelial
ATP release. Human urothelial RT4 cells were exposed to normal buffer or varying concentrations of inflammatory mediators
(bradykinin, histamine, and serotonin) in the presence or absence of hypotonic stretch stimuli (1 : 2 dilution of Krebs-Henseleit
buffer). Others have demonstrated that bradykinin increased stretch-induced ATP release; however, we observed no change in
control or stretch-induced ATP release with bradykinin. Pretreatment of RT4 cells with histamine or serotonin decreased stretch-
induced ATP release (𝑃 = 0.037, 𝑃 = 0.040, resp.). Previous studies have demonstrated increased ATP release in response to
inflammation utilising whole bladder preparations in contrast to our simple model of cultured urothelial cells. The current study
suggests that it is unlikely that there is a direct interaction between the release of inflammatorymediators and increasedATP release,
but rather more complex interactions occurring in response to inflammation that lead to increased bladder sensation.
1. Introduction
Inflammation is an important contributor to the aetiology
of a number of bladder dysfunctions. Pyuria (the presence
of white blood cells in the urine) has been associated with
lower urinary tract symptoms [1] and biopsy specimens
from patients with interstitial cystitis (IC)/painful bladder
syndrome (PBS) are commonly characterised by the presence
of inflammatory cells in the lamina propria, especially infil-
tration with mast cells [2–7]. Recently, histological evidence
for chronic inflammatory infiltrate has been demonstrated
in patients with refractory overactive bladder (OAB) [8]
together with pyuria in these patients [8, 9]. Proinflammatory
cytokines are increased in the urine from patients with OAB
[10–12].
These conditions (IC/PBS/OAB) are all characterised by
urinary urgency, together with frequency and nocturia [13].
It is believed that bladder sensation is associated with the
interaction of ATP with purinergic receptors located on
suburothelial afferent nerves [14, 15] and myofibroblasts [15].
ATP is released from the urothelium in response to stretch of
the urothelium triggered by bladder filling [16]. An increase
in stretch-induced ATP release has been demonstrated in
tissue strips and biopsies from patients with IC/PBS [17–
19] and OAB [20]. In addition, the concentration of ATP in
intravesical fluid has been shown to correlate with urinary
urgency as indicated by the volume at first desire to void in
patients with OAB [21, 22].
Similar to the changes in bladder histological structure
described with PBS/IC, chemical-induced cystitis causes
histological changes in the bladder wall including infiltration
of inflammatory cells (e.g., mast cells and macrophages) into
the submucosa [4–7], together with increased bladder weight
and oedema. In addition, chemical cystitis is associated with
activation of previously silent C-fibre afferents and sensiti-
sation of mechanosensitive A𝛿-fibres within the submucosa
[23–26].
The effect of inflammation causing an increase in urothe-
lial ATP release has been examined in animal models
of inflammation, including feline interstitial cystitis [27],
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cyclophosphamide cystitis [28], and ketamine cystitis [2].
However, the agents responsible for the increasedATP release
are unknown. The aim of this study was to examine the
effects of bradykinin, histamine, and serotonin, mediators
commonly associated with bladder inflammation, on urothe-
lial cell ATP release.
2. Materials and Methods
2.1. Cell Culture. Human urothelial RT4 cells (obtained from
the ECACC) were grown at 37∘Cwith 5%CO
2
inMcCoy’s 5A
culturemedium supplementedwith 10% foetal bovine serum,
100 units/mL of penicillin, 100𝜇g/mL of streptomycin, and
0.25 𝜇g/mL of fungizone. At confluence, cells were passaged
and then replated onto T75 flasks for continuous passage or
onto 24 well plates for use in ATP release when confluent
(approximately 3 to 5 days after passage).
2.2. ATP Release. ATP release was determined as previ-
ously described [29]. Urothelial cells were washed (three
times) with carbogenated Krebs-Henseleit solution (contain-










2.5, and D-glucose 11.7). The basal level of ATP
release was then determined by 10-minute incubation in
500𝜇L Krebs-Henseleit solution. Cells were then exposed to
normal Krebs-Henseleit (control) or the indicated concentra-
tion of mediator (bradykinin, histamine, and serotonin) in
the presence or absence of hypotonic Krebs-Henseleit (1 : 2
dilution of Krebs-Henseleit in distilled water). Hypotonic
Krebs-Henseleit was used as a stretch stimulus to examine the
effect of the mediators on stretch-induced ATP release. Cells
were treated for 10min before the supernatant (200𝜇L) was
collected and used for ATP determinations.
ATP concentration in the supernatant was measured
using the bioluminescence assay. Equal volumes of the cellu-
lar supernatant or ATP standard solutions (10−6 to 10−10M)
were mixed with the bioluminescence assay mix and the
luminescence generated was measured immediately using a
plate reader (BMG Labtech Polarstar). The ATP concentra-
tion in the cell supernatant was calculated relative to the
standard curve. Treatments were carried out in triplicate and
the mean ATP concentration (in nM) per treatment was
determined.
2.3. Statistics. As results are nonnormally distributed and
as such are expressed as median with interquartile range
(IQR); two different treatments were compared using a
Wilcoxon matched-pairs 𝑡-test. Dose response relationships
were examined using a sigmoidal dose response curve. All
statistics were performed using Graphpad Prims (version 6)
(San Diego, CA).
2.4. Materials. All cell culture reagents were purchased from
Invitrogen (Mount Waverley, Australia). Bioluminescence
ATP assay kit and mediators (bradykinin, histamine, and
serotonin) were from Sigma-Aldrich (Sydney, Australia). All
other reagents were of high analytical grade.
3. Results and Discussion
3.1. Effect of Bradykinin on Urothelial Cell ATP Release.
Bradykinin is a peptide neurotransmitter released from sen-
sory afferent nerves. Bradykinin release is closely associated
with inflammatory responses. Distension of the bladder has
been shown to stimulate release of bradykinin in patients
with IC indicating a potential role for this peptide in the
pathophysiology of this disorder [30]. Bradykinin exerts its
physiological actions via activation of B1 and B2 receptors.
Bradykinin B2 receptors are believed to be important in
inflammatory pain with animal models showing that block
of this receptor reduces inflammatory hyperalgesia [31, 32]. In
contrast, bradykinin B1 receptors are expressed at low levels
under normal circumstances with their expression upreg-
ulated following tissue damage or inflammation [33]. This
includes upregulation of bradykinin B1 receptors following
cystitis induced by intravesical injection of the detergent
Triton X100 [34]. Expression of bradykinin B1 receptors is
increased in biopsies obtained from patients with intersti-
tial cystitis [35] and, in cyclophosphamide-induced cystitis,
B1 receptor mediated bladder responses are significantly
increased [36, 37]. In addition, cyclophosphamide cystitis
induced a bladder hyperactivity that was dependent on
bradykinin B2 receptor activation andwas inhibited by the P2
receptor antagonist PPADS [38].This indicates a role for both
bradykinin and ATP in cyclophosphamide-induced cystitis
[38].
Other studies have observed that activation of bradykinin
B2 receptors by bradykinin increases stretch-induced ATP
release inUROtsa urothelial cells [39] and in primary cultures
of rat urothelial cells [38]. However, in the current study,
using urothelial RT4 cells, we saw no change in either control
or stretch-induced ATP release in the presence of bradykinin
(Figure 1). Hypotonic Krebs which was used as a positive
control was seen to induce an approximate threefold increase
in ATP release (baseline ATP release 34.06 (23.8–99.1) Nm;
stretch-induced ATP release 146.7 (72.4–217.6) nM, 𝑃 =
0.002). It is possible that the differences in these findings
relate to the individual cell lines used and that the bradykinin
receptors usually present on urothelial cells are not functional
on RT4 urothelial cells.
3.2. Effect of Mast Cell Mediators on Urothelial Cell ATP
Release. Infiltration of inflammatory cells such as mast cells
and macrophages into the bladder submucosa has been
demonstrated in cyclophosphamide-induced cystitis [3] and
ketamine-induced cystitis [2]. In addition, it is well known
that there is an increased density of mast cells in the bladder
wall in patients with IC [4–7].Mast cells lie in close proximity
to both urothelial cells and afferent fibres in the submucosa
of the urinary bladder, and degranulation of these cells has
been shown to release a wide range of neurotransmitters and
cytokines [38].
Mast cells are granulated immune system cells which
make up the major sensory arm of the innate immune
system [40]. Mast cells respond to allergens as well as non-
immunologic stimuli such as bacteria, chemicals, kinins, and
neuropeptides [41] to releasemediators such as histamine and
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Figure 1: Effect of bradykinin (1𝜇M, 𝑛 = 10) on baseline level of
ATP release and release induced by hypotonic media. Symbols are
representative of individual data points for the four groups. Data are
shown as median with interquartile range.
serotonin [42]. There are reports of increased concentrations
of histamine in urine from IC patients [41] and it is believed
that the pain associated with bladder filling in IC is related to
release of histamine from mast cells in the bladder wall [43].
In this study, the effect of mast cell mediators, histamine
and serotonin, on urothelial cell ATP release was examined.
Incubation of the RT4 cells with mast cell mediators, his-
tamine and serotonin, for 10 minutes had no effect on control
ATP release (Figures 2(a) and 2(c)). However, pretreatment
of urothelial cells with histamine or serotonin for a 10-minute
period prior to the addition of the hypotonic stretch stimulus
resulted in a decrease in ATP release in response to stretch
(Figure 2(a), 𝑃 = 0.037 for histamine; Figure 2(c), 𝑃 = 0.040
for serotonin). When the concentration response effect of
histamine on stretch-induced ATP release was determined,
it was seen to occur with an IC50 of 0.24𝜇M (0.19–2.8 𝜇M)
(Figure 2(b), 𝑛 = 6). This concentration is within the
histamine concentration range that has been reported in
urine from IC patients (3 to 31 ng/mL, equating to 24 to
280 nM) [43]. The slope of the concentration response curve
was fairly shallow with a Hill slope of −0.74 ± 0.19. A similar
concentration dependent inhibition of ATP release was also
elucidated for serotonin. In this instance, an IC50 of 1.7 nM
(<0.001 nM–50.0 𝜇M) was determined with a Hill slope of
−0.37 ± 0.24 (Figure 2(d), 𝑛 = 6).
While the effect of the mast cell mediators on urothelial
cell ATP release has never previously been examined, the
results obtainedwere somewhat unexpected. Previous studies
have shown an increase in ATP release from the bladder
in response to inflammation [17–19, 27, 28]. However, all
of these studies were conducted in whole tissue models of
inflammation. In these models, determining the causative
molecule or cell is complex as numerous interactions between
different cell types and mediators are occurring in the one
system which could change receptor expression in addition
tomediator release in response to the inflammatory stimulus.
The model used in the current study of cultured urothelial
cells is a much simpler model containing only a single cell
type and a single exogenously suppliedmediator. It is possible
that in the previous studies it was not the inflammatory
mediators themselves that were inducing the increase in
ATP release, but rather secondary changes that occurred in
response to the inflammation.Decreasing importance of ATP
in inflamed bladder is supported by findings that the P2
antagonist (PPADS) decreased voiding frequency in control
animals but not in cyclophosphamide treated animals [44].
Inflammation causes a number of changes in the blad-
der. For example, cyclophosphamide induced an increase
in COX2 protein expression in the urothelium, which was
dependent on release of mediators from mast cells [45];
in addition, cyclophosphamide also increases prostaglandin
E
2
production [46]. Prostaglandin E
2
has been shown to
increase urothelial cell ATP release [47]. It is also possible
that in response to inflammation there are changes in receptor
expression that would alter the response of urothelial cells
to these mast cell mediators. As mentioned previously,
bradykinin B1 receptors are expressed at very low levels under
normal conditions but are upregulated following inflamma-
tion [38]. It is possible that a similar phenomenon occurs
for histamine and serotonin receptors on the urothelium
although this has not been examined to date.
In addition, there are further changes that occur in
the inflamed bladder including defects in urothelial junc-
tion proteins, increased suburothelial inflammation, and
increased urothelial cell apoptosis [2]. Bladder inflammation
is associated with disruption of the glycosaminoglycan layer
that covers the urothelium [48–50]. Disruption of this layer
may allow urine contents to evoke irritation and inflam-
mation within the bladder wall. There is also increased
density of submucosal afferent nerves in the inflamed bladder
[43, 51, 52]. Urinary nerve growth factor (NGF) levels are
increased in patients with IC [53] and OAB [54]. In addi-
tion, cyclophosphamide-induced cystitis is associated with
increased NGF mRNA levels in the bladder [55], increases





receptors in afferent nerves [56]. It
is likely that the increase in NGF expression in patients
with bladder dysfunction is associated with the increased
density of suburothelial nerves in these patients. NGF is also
thought to alter expression of neurotransmitters, modulate
ion channels, and increase excitability of afferent nerves [57].
In rats, exogenously applied intravesical NGF can induce
bladder nociceptive responses and bladder overactivity [58].
In addition to NGF, inflammatory mediators themselves may
sensitise the afferent nerves to the effects of ATP [56, 59],
which could increase the bladder sensations in response to
bladder filling in the inflamed bladder.
4. Conclusions
It is well accepted that bladder inflammation is associated
with increased signalling from the bladder and increased
sensation. Studies using whole bladder models of inflam-
mation have shown that this is due to increased release of
ATP from the urothelium. However, based on the results of
the current study, it appears unlikely that there is a simple

























































































Figure 2: Effect of histamine (1𝜇M) ((a), 𝑛 = 10) and serotonin (1 𝜇M) ((c), 𝑛 = 10) on baseline level of ATP release and release induced by
hypotonic media. Data are shown as median with interquartile range. Concentration response relationships for the inhibition of ATP release
induced by hypotonic media in the presence of histamine ((b), 𝑛 = 10) and serotonin ((d), 𝑛 = 10).
interaction between the release of the inflammatory medi-
ators (bradykinin, histamine, and serotonin) and increased
ATP release leading to increased bladder sensation. It is more
likely that there are numerous factors involved in the interac-
tion between bladder inflammation and increased sensation.
These factors include alterations to receptor expression on the
urothelium and afferent nerves, increased density of afferent
nerves, and hyperresponsiveness of the afferent nerves, alter-
ing the neuronal component of afferent signalling.
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